Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJul 03, 2026
DataAggregated Company Financials
Companies20
  • 7D5.0%
  • 3M30.7%
  • 1Y-19.9%
  • YTD-2.0%

In the last week, the Healthcare industry is up 3.7%, with Novo Nordisk up 5.3%. In the past year, the industry is down 22%. As for the next few years, earnings are expected to grow by 1.7% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 03 Jul 2026DKK 1.9tDKK 469.2bDKK 147.1b21x13x4.1x
Sun, 31 May 2026DKK 1.7tDKK 468.5bDKK 147.0b20.7x11.8x3.7x
Tue, 28 Apr 2026DKK 1.6tDKK 447.3bDKK 129.9b18.1x12.1x3.5x
Thu, 26 Mar 2026DKK 1.4tDKK 447.7bDKK 130.0b16.5x11.1x3.2x
Sat, 21 Feb 2026DKK 1.8tDKK 447.5bDKK 130.9b18.7x13.6x4x
Mon, 19 Jan 2026DKK 2.2tDKK 454.1bDKK 137.0b18.6x16.4x4.9x
Wed, 17 Dec 2025DKK 1.9tDKK 453.7bDKK 136.8b17.1x13.6x4.1x
Fri, 14 Nov 2025DKK 1.9tDKK 453.5bDKK 136.1b17.9x14.2x4.2x
Sun, 12 Oct 2025DKK 2.2tDKK 447.6bDKK 141.8b18.2x15.4x4.9x
Tue, 09 Sep 2025DKK 2.0tDKK 447.2bDKK 141.6b19.9x14.4x4.5x
Thu, 07 Aug 2025DKK 1.7tDKK 432.1bDKK 131.0b28.2x13.2x4x
Sat, 05 Jul 2025DKK 2.5tDKK 422.9bDKK 124.4b30.8x19.7x5.8x
Mon, 02 Jun 2025DKK 2.5tDKK 423.9bDKK 124.7b30.4x19.9x5.8x
Wed, 30 Apr 2025DKK 2.4tDKK 409.2bDKK 121.3b22x19.4x5.7x
Fri, 28 Mar 2025DKK 2.6tDKK 409.5bDKK 121.3b22.9x21.6x6.4x
Sun, 23 Feb 2025DKK 3.3tDKK 410.0bDKK 121.4b28.1x27.6x8.2x
Tue, 21 Jan 2025DKK 3.0tDKK 387.4bDKK 111.3b28.4x27x7.7x
Thu, 19 Dec 2024DKK 4.0tDKK 387.4bDKK 111.3b30.8x35.6x10.2x
Sat, 16 Nov 2024DKK 3.7tDKK 387.3bDKK 110.9b31.6x33.5x9.6x
Mon, 14 Oct 2024DKK 4.2tDKK 372.0bDKK 107.1b37x39.3x11.3x
Wed, 11 Sep 2024DKK 4.5tDKK 372.0bDKK 107.2b35x41.9x12.1x
Fri, 09 Aug 2024DKK 4.4tDKK 369.1bDKK 106.9b36.2x41.4x12x
Sun, 07 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.3x46.2x13.8x
Tue, 04 Jun 2024DKK 4.7tDKK 355.2bDKK 106.2b36.1x43.9x13.1x
Thu, 02 May 2024DKK 4.6tDKK 341.4bDKK 99.6b33.9x45.8x13.4x
Sat, 30 Mar 2024DKK 4.5tDKK 341.2bDKK 99.6b39.2x45.4x13.3x
Mon, 26 Feb 2024DKK 4.4tDKK 340.1bDKK 98.9b38.2x44.2x12.9x
Wed, 24 Jan 2024DKK 3.7tDKK 320.5bDKK 90.0b35x41.5x11.6x
Fri, 22 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b33.2x40.4x11.3x
Sun, 19 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b33.7x40x11.2x
Tue, 17 Oct 2023DKK 3.7tDKK 305.5bDKK 82.2b29.9x44.5x12x
Thu, 14 Sep 2023DKK 3.5tDKK 305.5bDKK 82.2b35.1x43x11.6x
Sat, 12 Aug 2023DKK 3.3tDKK 301.3bDKK 81.0b41.3x40.8x11x
Mon, 10 Jul 2023DKK 2.9tDKK 287.0bDKK 75.5b39.4x38.9x10.2x
Price to Earnings Ratio

38.9x


Total Market Cap: DKK 2.9tTotal Earnings: DKK 75.5bTotal Revenue: DKK 287.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 29.2x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.7x which is lower than its 3-year average PE of 29.3x.
  • The 3-year average PS ratio of 8.5x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market4.04%
Healthcare4.98%
Biotech8.33%
Healthcare Services8.25%
Life Sciences5.15%
Pharma4.77%
Medical Equipment4.09%
Healthtech3.52%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 33.0x.
    • Analysts are expecting annual earnings growth of 19.8%, which is higher than its past year's earnings growth of 0.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 8.1% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 332.005.2%
+DKK 72.4b		-24.2%PE12.1x
GMAB GenmabDKK 1.87k8.9%
+DKK 9.4b		45.0%PE21.4x
COLO B ColoplastDKK 396.603.7%
+DKK 3.2b		-33.5%PE42.4x
DEMANT DemantDKK 279.203.6%
+DKK 2.0b		4.6%PE24.9x
AMBU B AmbuDKK 66.509.0%
+DKK 1.5b		-32.7%PE36.8x

Latest News

NOVO B
DKK 332.00
Novo Nordisk
7D
5.2%
1Y
-24.2%
AMBU B
DKK 66.50
Ambu
7D
9.0%
1Y
-32.7%
Narrative Update • Jul 01

AMBU B: Rising Competition Will Weigh On Future Share Performance

The analyst price target for Ambu has been reduced from DKK 78 to DKK 58, with analysts citing a more cautious near term outlook and rising competition as key reasons for the change. Analyst Commentary Recent commentary on Ambu reflects a more cautious tone, with bearish analysts flagging concerns around the company’s ability to deliver against expectations as competition increases.
GMAB
DKK 1,874.00
Genmab
7D
8.9%
1Y
45.0%
COLO B
DKK 396.60
Coloplast
7D
3.7%
1Y
-33.5%
Narrative Update • Jun 30

COLO B: Reset Expectations And New Products Will Shape Future Sentiment

The analyst price target for Coloplast has been revised from DKK 535 to DKK 345. This reflects a reset in valuation assumptions as analysts weigh recent target cuts against differing views on how the recent share selloff relates to company fundamentals and future P/E expectations.
BAVA
DKK 190.30
Bavarian Nordic
7D
6.8%
1Y
12.2%
ALK B
DKK 245.20
ALK-Abelló
7D
-4.2%
1Y
31.5%
Narrative Update • Jun 26

ALK B: Paediatric Allergy Approvals Will Drive Future Immunotherapy Leadership

Analysts have raised their price target on ALK-Abelló from DKK 243 to DKK 305, citing the company's position as a global leader in allergy immunotherapy as a key factor in their updated view. What’s in the News for ALK-Abelló UK regulator MHRA granted marketing authorisation for EURneffy 1 mg, the first needle free adrenaline treatment for anaphylaxis in children aged 4 and older weighing 15 to less than 30 kg, expanding ALK-Abelló’s emergency allergy treatment options in the UK.
ZEAL
DKK 305.00
Zealand Pharma
7D
6.6%
1Y
-16.0%
Narrative Update • Jun 25

ZEAL: Obesity Pipeline Progress And Buybacks Will Support Future Re Rating

Zealand Pharma's analyst price target has moved from about DKK 825 to roughly DKK 300, as analysts point to a longer timeline to unlock upside, lower peak sales expectations for key pipeline drugs, and revised assumptions that include a higher future P/E multiple and softer projected growth and margins. Analyst Commentary Recent Street research on Zealand Pharma highlights a mix of caution and optimism, with several analysts revisiting their assumptions on valuation, execution timelines, and the growth potential of key pipeline assets such as petrelintide and survodutide.
HLUN B
DKK 44.30
H. Lundbeck
7D
3.3%
1Y
26.4%
GUBRA
DKK 330.80
Gubra
7D
-0.8%
1Y
-24.7%
Narrative Update • Jun 24

GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside

Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.
DEMANT
DKK 279.20
Demant
7D
3.6%
1Y
4.6%
Narrative Update • Jun 23

DEMANT: Fair Value View Balances Growth Inflection Hopes With Execution Risks

Analysts have lifted their price expectations for Demant, with the consensus fair value estimate moving from DKK 240.32 to DKK 251.11. Recent research points to a higher price target range supported by updated views on growth, profitability and future P/E multiples.
STENO
DKK 1.03
Stenocare
7D
-1.9%
1Y
91.9%
PEG
DKK 0.083
Pharma Equity Group
7D
-4.8%
1Y
-36.0%